Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

WideCells's chief hails "very exciting times" for the group after Biovault agreement

Joao Andrade, chief executive at stem cells specialist WideCells Group (LON:WDC) talks to Proactive Investors about the definitive agreement the group signed in the UK with Biovault Technical,  which will facilitate the first sales of CellPlan to Biovault’s customer base.

"We are now very excited because we awere now able to reach an agreement with Biovault. Biovault is one of the cord blood banks in the world operating to the highest quality standards and that's really the type of company we would like to start working with," he says. "This is a very exciting time for us," he adds.

Discussing the commercial strategy for CellPlan sales he says: "we are expecting the uptake to be increasing as the year develops."

"This type of product is able to generate revenue for a number years."

Meet Faron Pharmaceuticals Ltd, Silence Therapeutics plc and Scancell Holdings Plc at our event, London , 01 November 2018. Register here »
View full WDC profile View Profile

WideCells Group Timeline

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use